Emerging cardiological issues during the COVID-19 pandemic

Eur J Clin Invest. 2020 Jul;50(7):e13270. doi: 10.1111/eci.13270. Epub 2020 Jun 17.

Authors

Bert R Everaert¹, Jan Muylle², Theodorus Bartholomeus Twickler^{3

4}

Affiliations

¹ Department of Cardiology, AZ Monica Hospital, Antwerp, Belgium.
² Department of Intensive Care, AZ Monica Hospital, Antwerp, Belgium.
³ Department of Endocrinology, Diabetology and Metabolic Disease, AZ Monica Hospital, Antwerp, Belgium.
⁴ Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium.

No abstract available

Keywords: COVID-19; SARS-CoV-2; arterial thrombosis; biomarkers; myocarditis; proarrythmia.

MeSH terms

Antiviral Agents / adverse effects
Arrhythmias, Cardiac / chemically induced
Arrhythmias, Cardiac / physiopathology*
Betacoronavirus
COVID-19
COVID-19 Drug Treatment
Coronary Artery Disease / epidemiology
Coronavirus Infections / blood
Coronavirus Infections / drug therapy
Coronavirus Infections / epidemiology
Coronavirus Infections / physiopathology*
Cytokine Release Syndrome / physiopathology
Delivery of Health Care*
Heart Failure / physiopathology*
Humans
Hydroxychloroquine / adverse effects
Hypertension / epidemiology
Hypoxia / physiopathology
Mortality
Myocardial Ischemia / physiopathology*
Myocarditis / physiopathology*
Oxidative Stress
Pandemics
Pneumonia, Viral / blood
Pneumonia, Viral / drug therapy
Pneumonia, Viral / epidemiology
Pneumonia, Viral / physiopathology*
Risk Factors
SARS-CoV-2
Severity of Illness Index
Takotsubo Cardiomyopathy / physiopathology*
Thrombophilia / blood
Thrombophilia / physiopathology

Substances

Antiviral Agents
Hydroxychloroquine